Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies

[Image: see text] Inhibition of the androgen receptor (AR) is the mainstay treatment for advanced prostate cancer. Ralaniten (formally EPI-002) prevents AR transcriptional activity by binding to its N-terminal domain (NTD) which is essential for transcriptional activity. Ralaniten acetate (EPI-506)...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:ACS Pharmacol Transl Sci
Autori principali: Obst, Jon K., Wang, Jun, Jian, Kunzhong, Williams, David E., Tien, Amy H., Mawji, Nasrin, Tam, Teresa, Yang, Yu Chi, Andersen, Raymond J., Chi, Kim N., Montgomery, Bruce, Sadar, Marianne D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Chemical Society 2019
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7088963/
https://ncbi.nlm.nih.gov/pubmed/32259077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsptsci.9b00065
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi